Tradestie Institutional Equity Comparison Engine

ACTU vs SABA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SABA Overall Edge

SABA Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Saba Capital Income & Opportunities Fund II (SABA) driven by superior Momentum & Technical, Options & Structure while ACTU counters with relative strength in Growth & Margin. Fundamentally, ACTU trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SABA at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ACTU sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against SABA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ACTU N/M vs SABA N/M Fwd P/E
Growth & Margin Winner ACTU
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner SABA
1Y -96.2% vs -16.0% ยท 52W Pos 1% vs 4%
Options & Structure Winner SABA
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
ACTU NASDAQ
Actuate Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$0.23
+5.38% 1D
Market Cap $12.9M
1M Return -56.35%
1Y Return -96.15%
Forward P/E N/M
Unified AI Score
35.1 / 100 SELL
Tech 25.0 Fund 37.0 Flow 50.0 Mom 49.0
SABA NYSE
Saba Capital Income & Opportunities Fund II
Institutional Equity
$7.33
-0.27% 1D
Market Cap $251.8M
1M Return -3.68%
1Y Return -16.04%
Forward P/E N/M
Unified AI Score
44.2 / 100 HOLD
Tech 38.0 Fund 55.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACTU -96.15% SABA -16.04% Spread: +80.11 pp (SABA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACTU TTM Op. Margin: 0.0% SABA TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACTU vs SABA. Trailing 12-month operating profitability (ACTU 0.0% vs SABA N/A) and valuation multiples (ACTU N/M vs SABA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACTU (4) vs SABA (4)
Institutional Metric ACTU SABA Criterion Row Winner
Market Capitalization Scale $12.9M $251.8M Larger Scale SABA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth ACTU
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin ACTU
Net Profit Margin Profitability 0.0% N/A Higher Margin ACTU
Return on Equity (ROE) Capital Efficiency -553.8% N/A Higher ROE ACTU
52-Week Range Position Momentum 1% ($0โ€“$8) 4% ($7โ€“$9) Stronger Trend SABA
Beta / 30D Volatility Risk Regime 1.64ฮฒ ยท 114% Vol 0.37ฮฒ ยท 13% Vol Lower Realized Risk SABA
Unified Institutional Score Composite Signal 35.1 / 100 (SELL) 44.2 / 100 (HOLD) Higher Composite SABA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACTU vs SABA Buy Guide
ACTU BREAKDOWN
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ACTU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SABA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SABA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACTU nor SABA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.